Chemotherapy response monitoring of colorectal liver metastases by dynamic Gd-DTPA-enhanced MRI perfusion parameters and 18F-FDG PET metabolic rate

Journal of Nuclear Medicine

Volumn 50, Issue 11, 2009, Pages 1777-1784

  Vriens, Dennis ^a   Van Laarhoven, Hanneke W M ^a   Van Asten, Jack J A ^a   Krabbe, Paul F M ^a   Visser, Eric P ^a   Heerschap, Arend ^a   Punt, Cornelis J A ^a   De Geus Oei, Lioe Fee ^a   Oyen, Wim J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

18F FDG; Chemotherapy; Colorectal carcinoma; DCE MRI; PET; Survival; Therapy monitoring

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; GADOLINIUM PENTETATE; GLUCOSE; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; EXTRACELLULAR SPACE; EXTRAVASCULAR SPACE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IN VIVO STUDY; LIVER METASTASIS; MALE; METABOLIC RATE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERFUSION WEIGHTED IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; TUMOR VASCULARIZATION; TUMOR VOLUME;

AGED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; GADOLINIUM DTPA; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 70350707775     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.064790     Document Type: Article

References (33)

1. Punt CJ. New options and old dilemmas in the treatment of patients with advanced colorectal cancer. Ann Oncol. 2004;15:1453-1459. (Pubitemid 39409733)
2. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10:223-232. (Pubitemid 29463104)
3. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3:1-7.
4. Devries AF, Griebel J, Kremser C, et al. Tumor microcirculation evaluated by dynamic magnetic resonance imaging predicts therapy outcome for primary rectal carcinoma. Cancer Res. 2001;61:2513-2516. (Pubitemid 32685831)
5. George ML, Dzik-Jurasz AS, Padhani AR, et al. Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. Br J Surg. 2001;88:1628-1636.
6. Pickles MD, Lowry M, Manton DJ, Gibbs P, Turnbull LW. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2005;91: 1-10. (Pubitemid 40684933)
7. Delille JP, Slanetz PJ, Yeh ED, Halpern EF, Kopans DB, Garrido L. Invasive ductal breast carcinoma response to neoadjuvant chemotherapy: noninvasive monitoring with functional MR imaging pilot study. Radiology. 2003;228:63-69. (Pubitemid 36736070)
8. Thukral A, Thomasson DM, Chow CK, et al. Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab-initial experience. Radiology. 2007;244:727-735. (Pubitemid 47292083)
9. de Geus-Oei LF, Wiering B, Krabbe PF, Ruers TJ, Punt CJ, Oyen WJ. FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma. Ann Oncol. 2006;17:1650-1655. (Pubitemid 44680885)
10. 18F-FDG PET in patients with non-small cell lung cancer. J Nucl Med. 2007;48:1592-1598.
11. de Geus-Oei LF, van Laarhoven HW, Visser EP, et al. Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. Ann Oncol. 2008;19:348-352. (Pubitemid 351201718)
12. Hittmair K, Gomiscek G, Langenberger K, Recht M, Imhof H, Kramer J. Method for the quantitative assessment of contrast agent uptake in dynamic contrastenhanced MRI. Magn Reson Med. 1994;31:567-571. (Pubitemid 24129954)
13. van Laarhoven HW, Rijpkema M, Punt CJ, et al. Method for quantitation of dynamic MRI contrast agent uptake in colorectal liver metastases. J Magn Reson Imaging. 2003;18:315-320. (Pubitemid 37046512)
14. Larsson HB, Stubgaard M, Frederiksen JL, Jensen M, Henriksen O, Paulson OB. Quantitation of blood-brain barrier defect by magnetic resonance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumors. Magn Reson Med. 1990;16:117-131. (Pubitemid 20353802)
15. van Laarhoven HW, de Geus-Oei LF, Wiering B, et al. Gadopentetate dimeglumine and FDG uptake in liver metastases of colorectal carcinoma as determined with MR imaging and PET. Radiology. 2005;237:181-188. (Pubitemid 41346162)
16. 18F-FDG PET studies. J Nucl Med. 2006;47:945-949.
17. 18F]FDG-PET. Q J Nucl Med Mol Imaging. 2009;53:224-244.
18. Willemsen AT, van den Hoff J. Fundamentals of quantitative PET data analysis. Curr Pharm Des. 2002;8:1513-1526. (Pubitemid 34693066)
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
20. 18F] fluorodeoxyglucose PET in the diagnosis of breast cancer: initial experience. Eur Radiol. 2001;11:2058-2070.
21. Semple SI, Gilbert FJ, Redpath TW, et al. The relationship between vascular and metabolic characteristics of primary breast tumours. Eur Radiol. 2004;14:2038-2045.
22. Evans SM, Hahn SM, Magarelli DP, Koch CJ. Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation. Am J Clin Oncol. 2001;24:467-472.
23. Burgman P, Odonoghue JA, Humm JL, Ling CC. Hypoxia-induced increase in FDG uptake in MCF7 cells. J Nucl Med. 2001;42:170-175. (Pubitemid 32104796)
24. Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med. 1995;36:1625-1632.
25. Semple SI, Staff RT, Heys SD, et al. Baseline MRI delivery characteristics predict change in invasive ductal breast carcinoma PET metabolism as a result of primary chemotherapy administration. Ann Oncol. 2006;17: 1393-1398.
26. Artemov D, Solaiyappan M, Bhujwalla ZM. Magnetic resonance pharmacoangiography to detect and predict chemotherapy delivery to solid tumors. Cancer Res. 2001;61:3039-3044. (Pubitemid 32691952)
27. Wasser K, Klein SK, Fink C, et al. Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution. Eur Radiol. 2003;13:80-87. (Pubitemid 36790494)
28. Wasser K, Sinn HP, Fink C, et al. Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy. Eur Radiol. 2003;13:1213-1223. (Pubitemid 36790621)
29. Hayes C, Padhani AR, Leach MO. Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed. 2002;15:154-163. (Pubitemid 34213405)
30. van Laarhoven HW, Klomp DW, Rijpkema M, et al. Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil. NMR Biomed. 2007;20:128-140. (Pubitemid 46470935)
31. Flaherty KT, Rosen MA, Heitjan DF, et al. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther. 2008;7:496-501.
32. Hahn OM, Yang C, Medved M, et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008;26:4572-4578.
33. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 2006;24:769-777.